{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T07:38:02Z","timestamp":1782632282484,"version":"3.54.5"},"reference-count":64,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Siglec-XII, encoded by SIGLEC12, is a unique sialic acid-binding immunoglobulin-like lectin. It lacks a highly conserved R122 residue for sialic acid recognition in humans. Although it is upregulated in bladder cancer (BCa), its role in tumorigenesis remains largely unexplored. This study aims to investigate the expression patterns of SIGLEC12 in BCa and its correlation with disease features. Materials and Methods: An integrated analysis of transcriptomic data and clinical profiles was conducted using various databases and tools, including UALCAN, GEPIA, TIMER, CAMOIP, and CPADs. The analyses encompassed SIGLEC12 expression, survival rates, immune infiltration levels, promoter methylation, and correlation with drug response. Results: SIGLEC12 expression was higher in both low-grade papillary and high-grade invasive non-papillary BCa. Higher SIGLEC12 expression resulting from low promoter hypomethylation was detected at the stage II-IV of BCa, and was unrelated to disease stages and metastatic stages. Elevated SIGLEC12 expression correlated with increased immune cell infiltration, higher expression of oncogenic and immune checkpoint blockade-related genes, and drug resistance signatures. Mutation analysis confirmed the absence of the canonical R122 missense mutation, indicating that the structural integrity and potential functionality of Siglec-XII are preserved in BCa. Conclusions: SIGLEC12 may have sialic acid recognition functions and serve as a potential early biomarker of BCa.<\/jats:p>","DOI":"10.3390\/medicina61111894","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:14:02Z","timestamp":1761182042000},"page":"1894","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Decoding SIGLEC12 in Bladder Cancer: In Silico Profiling of Expression, Tumor\u2013Immune Interactions, and Prognostic Impact"],"prefix":"10.3390","volume":"61","author":[{"given":"Varsha","family":"Rathore","sequence":"first","affiliation":[{"name":"Chemical Biology and Molecular Biophysics, Taiwan International Graduate Program, Academia Sinica, Taipei 115201, Taiwan"},{"name":"Institute of Biotechnology, College of Life Sciences and Medicine, National Tsing Hua University, Hsinchu 300044, Taiwan"},{"name":"Department of Pharmacology, College of Medicine, National Taiwan University, Taipei 100233, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3207-734X","authenticated-orcid":false,"given":"Wan-Wan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Medicine, National Taiwan University, Taipei 100233, Taiwan"},{"name":"Graduate Institute of Medical Sciences, Taipei Medical University, Taipei 110, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41585-023-00806-2","article-title":"The Sex Gap in Bladder Cancer Survival\u2014A Missing Link in Bladder Cancer Care?","volume":"21","author":"Toren","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.14740\/wjon1210","article-title":"Non-Muscle Invasive Bladder Cancer: A Review of the Current Trend in Africa","volume":"10","author":"Cassell","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/cncy.22603","article-title":"Insights on Recent Innovations in Bladder Cancer Immunotherapy","volume":"130","author":"Smith","year":"2022","journal-title":"Cancer Cytopathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder Cancer","volume":"9","author":"Hansel","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pathol-012513-104703","article-title":"Origins of Bladder Cancer","volume":"11","author":"Czerniak","year":"2016","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.5858\/arpa.2018-0329-RA","article-title":"Bladder Cancer in the Genomic Era","volume":"143","author":"Guo","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/ni.3552","article-title":"The Mucin MUC1 Modulates the Tumor Immunological Microenvironment through Engagement of the Lectin Siglec-9","volume":"17","author":"Beatson","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/nn5061964","article-title":"Targeted Delivery of a Sialic Acid-Blocking Glycomimetic to Cancer Cells Inhibits Metastatic Spread","volume":"9","author":"Boltje","year":"2015","journal-title":"ACS Nano"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/jcp.22068","article-title":"A Novel Sialyltransferase Inhibitor AL10 Suppresses Invasion and Metastasis of Lung Cancer Cells by Inhibiting Integrin-mediated Signaling","volume":"223","author":"Chiang","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bcp.2011.05.018","article-title":"Targeting Siglecs\u2014A Novel Pharmacological Strategy for Immuno- and Glycotherapy","volume":"82","author":"Jandus","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1073\/pnas.1409580111","article-title":"Engagement of Myelomonocytic Siglecs by Tumor-Associated Ligands Modulates the Innate Immune Response to Cancer","volume":"111","author":"Pearce","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lim, J., Sari-Ak, D., and Bagga, T. (2021). Siglecs as Therapeutic Targets in Cancer. Biology, 10.","DOI":"10.3390\/biology10111178"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/bloodadvances.2021006805","article-title":"Targeting Hypersialylation in Multiple Myeloma Represents a Novel Approach to Enhance NK Cell\u2013Mediated Tumor Responses","volume":"6","author":"Daly","year":"2022","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T Cell Therapy: Current Limitations and Potential Strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T Cell Engagers: An Emerging Therapy for Management of Hematologic Malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.dci.2018.05.008","article-title":"Siglecs: A Journey through the Evolution of Sialic Acid-Binding Immunoglobulin-Type Lectins","volume":"86","author":"Goldammer","year":"2018","journal-title":"Dev. Comp. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"19843","DOI":"10.1074\/jbc.M502041200","article-title":"Siglec-5 (CD170) Can Mediate Inhibitory Signaling in the Absence of Immunoreceptor Tyrosine-Based Inhibitory Motif Phosphorylation","volume":"280","author":"Avril","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and Their Roles in the Immune System","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/14728222.2019.1667977","article-title":"The Sialoglycan-Siglec Glyco-Immune Checkpoint\u2014A Target for Improving Innate and Adaptive Anti-Cancer Immunity","volume":"23","year":"2019","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/gbe\/evaa125","article-title":"Multiple Genomic Events Altering Hominin SIGLEC Biology and Innate Immunity Predated the Common Ancestor of Humans and Archaic Hominins","volume":"12","author":"Khan","year":"2020","journal-title":"Genome Biol. Evol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"40282","DOI":"10.1074\/jbc.M105926200","article-title":"A Second Uniquely Human Mutation Affecting Sialic Acid Biology","volume":"276","author":"Angata","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.111.00823","article-title":"Pharmacogenomic Association of Nonsynonymous SNPs in SIGLEC12, A1BG, and the Selectin Region and Cardiovascular Outcomes","volume":"62","author":"McDonough","year":"2013","journal-title":"Hypertension"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"23003","DOI":"10.1074\/jbc.M111.244152","article-title":"SIGLEC12, a Human-Specific Segregating (Pseudo) Gene, Encodes a Signaling Molecule Expressed in Prostate Carcinomas","volume":"286","author":"Mitra","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23816","DOI":"10.1074\/jbc.M102394200","article-title":"Identification and Characterization of S2V, a Novel Putative Siglec That Contains Two V Set Ig-like Domains and Recruits Protein-Tyrosine Phosphatases SHPs","volume":"276","author":"Yu","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1096\/fba.2020-00092","article-title":"Human-Specific Polymorphic Pseudogenization of SIGLEC12 Protects against Advanced Cancer Progression","volume":"3","author":"Siddiqui","year":"2021","journal-title":"FASEB Bioadv"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e24286","DOI":"10.1016\/j.heliyon.2024.e24286","article-title":"Analysis of SIGLEC12 Expression, Immunomodulation and Prognostic Value in Renal Cancer Using Multiomic Databases","volume":"10","author":"Ogbodo","year":"2024","journal-title":"Heliyon"},{"key":"ref_28","first-page":"181539","article-title":"Human-Specific Elimination of Epithelial Siglec-XII Suppresses the Risk of Inflammation Driven Colorectal Cancers","volume":"9","author":"Cuello","year":"2024","journal-title":"JCI Insight"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: Exploring the World\u2019s Knowledge of Somatic Mutations in Human Cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lin, A., Qi, C., Wei, T., Li, M., Cheng, Q., Liu, Z., Luo, P., and Zhang, J. (2022). CAMOIP: A Web Server for Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-Cancer. Brief. Bioinform., 23.","DOI":"10.1093\/bib\/bbac129"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"i436","DOI":"10.1093\/bioinformatics\/btz363","article-title":"Comprehensive Evaluation of Transcriptome-Based Cell-Type Quantification Methods for Immuno-Oncology","volume":"35","author":"Sturm","year":"2019","journal-title":"Bioinformatics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/bs.mie.2019.05.056","article-title":"Deconvoluting Tumor-Infiltrating Immune Cells from RNA-Seq Data Using quanTIseq","volume":"636","author":"Plattner","year":"2020","journal-title":"Methods Enzymol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7362","DOI":"10.1038\/s41467-024-50618-0","article-title":"Community Assessment of Methods to Deconvolve Cellular Composition from Bulk Gene Expression","volume":"15","author":"White","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Li, K., Yang, H., Lin, A., Xie, J., Wang, H., Zhou, J., Carr, S.R., Liu, Z., Li, X., and Zhang, J. (2024). CPADS: A Web Tool for Comprehensive Pancancer Analysis of Drug Sensitivity. Brief. Bioinform., 25.","DOI":"10.1093\/bib\/bbae237"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Crocetto, F., Amicuzi, U., Musone, M., Magliocchetti, M., Di Lieto, D., Tammaro, S., Pastore, A.L., Fuschi, A., Falabella, R., and Ferro, M. (2025). Liquid Biopsy: Current Advancements in Clinical Practice for Bladder Cancer. J. Liq. Biopsy, 9.","DOI":"10.1016\/j.jlb.2025.100310"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e180282","DOI":"10.1172\/JCI180282","article-title":"Sialylated Glycoproteins Suppress Immune Cell Killing by Binding to Siglec-7 and Siglec-9 in Prostate Cancer","volume":"134","author":"Wen","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e010580","DOI":"10.1136\/jitc-2024-010580","article-title":"Siglec-15 Antibody\u2013GM-CSF Chimera Suppresses Tumor Progression via Reprogramming Tumor-Associated Macrophages","volume":"13","author":"Ma","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","article-title":"Siglec-15 as an Immune Suppressor and Potential Target for Normalization Cancer Immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e009404","DOI":"10.1136\/jitc-2024-009404","article-title":"Identification of Siglec-10 as a New Dendritic Cell Checkpoint for Cervical Cancer Immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Barone, B., Finati, M., Cinelli, F., Fanelli, A., Del Giudice, F., De Berardinis, E., Sciarra, A., Russo, G., Mancini, V., and D\u2019Altilia, N. (2023). Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence. J. Pers. Med., 13.","DOI":"10.3390\/jpm13030512"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1749-6632.2011.06362.x","article-title":"Siglecs as Sensors of Self in Innate and Adaptive Immune Responses","volume":"1253","author":"Paulson","year":"2012","journal-title":"Ann. N. Y Acad. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1R","DOI":"10.1093\/glycob\/cwj008","article-title":"Siglecs\u2014The Major Subfamily of I-Type Lectins","volume":"16","author":"Varki","year":"2006","journal-title":"Glycobiology"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Journo, G., Ahuja, A., Dias-Polak, D., Eran, Y., Bergman, R., and Shamay, M. (2021). Global CpG DNA Methylation Footprint in Kaposi\u2019s Sarcoma. Front. Cell Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.666143"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ani\u0107, P., Golubi\u0107 Tali\u0107, J., Bo\u017einovi\u0107, K., Dediol, E., Mravak-Stipeti\u0107, M., Grce, M., and Milutin Ga\u0161perov, N. (2023). Methylation of Immune Gene Promoters in Oral and Oropharyngeal Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097698"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1807291","DOI":"10.1080\/2162402X.2020.1807291","article-title":"Expression Signature, Prognosis Value, and Immune Characteristics of Siglec-15 Identified by Pan-Cancer Analysis","volume":"9","author":"Li","year":"2020","journal-title":"OncoImmunology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/14728222.2017.1297798","article-title":"Tp53 and Its Potential Therapeutic Role as a Target in Bladder Cancer","volume":"21","author":"Ciccarese","year":"2017","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Qiu, Y., Ke, S., Chen, J., Qin, Z., Zhang, W., Yuan, Y., Meng, D., Zhao, G., Wu, K., and Li, B. (2022). FOXP3+ Regulatory T Cells and the Immune Escape in Solid Tumours. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.982986"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/2326-6066.CIR-18-0711","article-title":"IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell","volume":"7","author":"Shao","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"De Streel, G., and Lucas, S. (2021). Targeting Immunosuppression by TGF-\u03921 for Cancer Immunotherapy. Biochem. Pharmacol., 192.","DOI":"10.1016\/j.bcp.2021.114697"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Rathore, V., Cheng, C.-Y., Chen, S.-P., Lin, C.-Y., Chang, C.-R., and Lin, W.-W. (2025). CASK Promotes Prostate Cancer Progression via Kinase-Dependent Activation of AKT. Int. J. Biol. Macromol., 311.","DOI":"10.1016\/j.ijbiomac.2025.143965"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.trecan.2019.05.010","article-title":"Integrative Approaches to Cancer Immunotherapy","volume":"5","author":"Szeto","year":"2019","journal-title":"Trends Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wo\u0142\u0105cewicz, M., Hrynkiewicz, R., Grywalska, E., Suchojad, T., Leksowski, T., Roli\u0144ski, J., and Nied\u017awiedzka-Rystwej, P. (2020). Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives. Cancers, 12.","DOI":"10.3390\/cancers12051181"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Xiang, C., Chen, J., and Fu, P. (2017). HGF\/Met Signaling in Cancer Invasion: The Impact on Cytoskeleton Remodeling. Cancers, 9.","DOI":"10.3390\/cancers9050044"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00428-017-2064-8","article-title":"In Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC), High KRT20 and Low KRT5 mRNA Expression Identify the Luminal Subtype and Predict Recurrence and Survival","volume":"470","author":"Breyer","year":"2017","journal-title":"Virchows Arch."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1080\/15384101.2022.2054095","article-title":"KRT6A Expedites Bladder Cancer Progression, Regulated by miR-31-5p","volume":"21","author":"Chen","year":"2022","journal-title":"Cell Cycle"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Yu, W., Yao, D., Ma, X., Hou, J., and Tian, J. (2025). A Novel Efferocytosis-Related Gene Signature for Predicting Prognosis and Therapeutic Response in Bladder Cancer. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-04037-w"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Tai, G., Ranjzad, P., Marriage, F., Rehman, S., Denley, H., Dixon, J., Mitchell, K., Day, P.J.R., and Woolf, A.S. (2013). Cytokeratin 15 Marks Basal Epithelia in Developing Ureters and Is Upregulated in a Subset of Urothelial Cell Carcinomas. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081167"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2013.53.2465","article-title":"Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity","volume":"32","author":"Plimack","year":"2014","journal-title":"JCO"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00280-019-03960-w","article-title":"Phase 1 Study of Veliparib (ABT-888), a Poly (ADP-Ribose) Polymerase Inhibitor, with Carboplatin and Paclitaxel in Advanced Solid Malignancies","volume":"84","author":"Appleman","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11060-014-1612-1","article-title":"Single Agent Efficacy of the VEGFR Kinase Inhibitor Axitinib in Preclinical Models of Glioblastoma","volume":"121","author":"Lu","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"16275","DOI":"10.3390\/ijms160716275","article-title":"Experimental Evidence Shows Salubrinal, an eIF2\u03b1 Dephosphorylation Inhibitor, Reduces Xenotoxicant-Induced Cellular Damage","volume":"16","author":"Matsuoka","year":"2015","journal-title":"Int. J. Mol. Sci."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1894\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T04:32:15Z","timestamp":1761280335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":64,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["medicina61111894"],"URL":"https:\/\/doi.org\/10.3390\/medicina61111894","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]}}}